Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/34878


Antivirals - A Broad Market Overview


Description: Since the discovery of the first vaccination against an infectious disease (smallpox) by Edward Jenner in 1798, many additional vaccinations have been developed, dramatically decreasing incidence of viral infections such as measles, diphtheria and polio. However, the treatment of viral infections has proved far less straightforward with the development of antiviral therapies lagging behind advances in other infectious disease fields. Ongoing advances in cell culture techniques and drug discovery technology are only now facilitating an increase in antiviral R&D and new product launches are driving market growth and commercial interest in certain viral indications. While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this field face. Curative therapies are rare, drug resistance is becoming increasingly problematic and the introduction of novel vaccines threatens the market for many antivirals. Scope of this Report: - Detailed analysis of the global antiviral market, focusing on HIV, hepatitis, herpes and influenza - Assessment of each viral indication, characterized by 2002 market value, forecasted growth and current clinical unmet need - Insight into antiviral research and development activity - Discussion of the various options for more effective life cycle and portfolio management strategy Report Highlights: - The antiviral market is set to demonstrate positive growth up until 2011, driven predominantly by the increased availability of hepatitis B treatments. - Growing disease awareness, particularly of recently characterized infections, such as HCV, will continue to drive patient potential by increasing presentation rates. - Broad-spectrum antivirals present companies with good opportunities to implement life-cycle management initiatives. Key Reasons to Buy this Report: - Determine the characteristics that define antiviral markets and their relative potential - Understand the key drivers and resistors of antiviral market growth - Identify life-cycle management options that help to optimize and extend product revenue ". Relative to other therapeutic areas, commercial attractiveness of the antiviral market is high and set to increase, mainly driven by novel HIV and hepatitis B products."


Contents: Drivers AND Trends

Unlike many pharmaceutical sectors, the relative potential of the antiviral market is set to increase. Ongoing advances in cell culture techniques and drug discovery technology are only now facilitating an increase in antiviral R&D and new product launches are driving market growth and commercial interest in certain viral indications. Unmet need is very high and the range of different diseases provides opportunity for niche marketing strategies, reducing competitive intensity. However, this diversity also presents companies with investment dilemmas regarding resource distribution and prioritization.

Market Overview

How does the antiviral market look now, and in the future? This section provides:
- A summary of the current antiviral market size, split by key indications
- Market forecasts up to 2010
- A review of key players in the antiviral market

Disease Focus

What are the key indications in the antivirals market and what products are currently available to treat these? This section provides an overview of key antiviral fields, highlighting the most important characteristics of each. The focus of this section is on HIV, Hepatitis B and C and Herpes, although influenza and RSV are also reviewed.

Future Focus

Which market sectors are showing the most R&D activity, and which have the biggest growth potential? This section focuses on future product development in each sector, comparing R&D activity with market growth up to 2010. Strategic recommendations regarding product lifecycle and portfolio management are also reviewed.

List of Tables

Table 1: Global antiviral sales by indication, 2002-10
Table 2: HIV prevalence in the seven major markets, 2002
Table 3: HIV prevalence in different world regions, 2002
Table 4: Products available to treat HIV infection, Q2/Q3 2003
Table 5: Breakdown of 2002 sales data and 2010 forecasts by drug class
Table 6: US HSV prevalence rates
Table 7: CMV high-risk populations across the seven major markets, 2002
Table 8: Key brand products used for the treatment of various herpes types
Table 9: Sales forecasts for the HSV and CMV markets up to 2010
Table 10: HCV prevalence in the seven major markets, 2002
Table 11: Key products available for HCV treatment, 2003
Table 12: HBV prevalence in the seven major markets, 2002
Table 13: Approved HBV therapies, mid-2003
Table 14: Sales forecasts for HBV drug classes up to 2010
Table 15: Marketed products used for influenza treatment, 2003
Table 16: Drugs available on the RSV market, 2003

List of Figures

Figure 1: Drivers and resistors of antiviral market growth
Figure 2: Market attractiveness matrix of selected pharmaceutical fields, 2002-11
Figure 3: Global antiviral sales, 2002
Figure 4: Global antiviral sales forecasts, 2010
Figure 5: Global antiviral sales by company and indication, 2002
Figure 6: Typical progression of HIV infection with and without treatment
Figure 7: HIV company market share in 2002 and 2010
Figure 8: HCV disease progression
Figure 9: HBV disease progression
Figure 10: No. US laboratory confirmed influenza isolates during the 2002-03 season
Figure 11: Typical rates of RSV infection, with patient population numbers for the seven major markets, 2002
Figure 12: Antiviral R&D, preclinical to registration, 2003
Figure 13: Growth of the antiviral market sectors relative to R&D activity and 2002 market size
Figure 14: GSK's life-cycle management of lamivudine, 1996-2002




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/34878

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 26/11/2009 15:55:38
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Antivirals - A Broad Market Overview
Web Address:
http://www.researchandmarkets.com/reports/34878
Office Code:
OC8HJNMPMSTQQ

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic €1,075.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 26/11/2009 15:55:38

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)